Tandem Capital Management Corp Exelixis, Inc. Transaction History

Tandem Capital Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$15.84 - $21.88 $152,856 - $211,142	-9,650 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$16.3 - $21.14 $94,051 - $121,977	-5,770 Reduced 37.42%	9,650 $204,000
Q4 2020 Feb 01, 2021	BUY	$18.39 - $24.8 $26,113 - $35,216	1,420 Added 10.14%	15,420 $309,000
Q3 2020 Nov 03, 2020	BUY	$20.67 - $26.94 $90,948 - $118,536	4,400 Added 45.83%	14,000 $342,000
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $158,016 - $263,232	9,600 New	9,600 $228,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Tandem Capital Management Corp , based on Form 13F filings with the SEC.

Stay updated on Tandem Capital Management Corp with notifications on news.